Transcripts Novartis AG Swiss Exchange

Actions

NOVNEE

CH0038459415

Produits pharmaceutiques

Marché Fermé - Swiss Exchange Autres places de cotation 17:30:00 03/07/2026			Varia. 5j.	Varia. 1 janv.
128,28 ^CHF	-0,67 %		+1,62 %	+16,87 %

03/07	Bourse Zurich: le SMI garde le cap après son record historique	AW
03/07	Bourse Zurich: début de séance de bonne humeur	AW

Transcripts

28/04	Transcript : Novartis AG, Q1 2026 Earnings Call, Apr 28, 2026
06/03	Transcript : Novartis AG - Shareholder/Analyst Call
04/02	Transcript : Novartis AG, Q4 2025 Earnings Call, Feb 04, 2026
12/01	Transcript : Novartis AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM
01/12	Transcript : Novartis AG - Special Call
21/11	Transcript : Novartis AG - Shareholder/Analyst Call
20/11	Transcript : Novartis AG - Shareholder/Analyst Call
30/10/25	Transcript : Novartis AG - Special Call
28/10/25	Transcript : Novartis AG, Q3 2025 Earnings Call, Oct 28, 2025
17/07/25	Transcript : Novartis AG, Q2 2025 Earnings Call, Jul 17, 2025
29/04/25	Transcript : Novartis AG, Q1 2025 Earnings Call, Apr 29, 2025
31/01/25	Transcript : Novartis AG, Q4 2024 Earnings Call, Jan 31, 2025
14/01/25	Transcript : Novartis AG Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 08:15 AM
09/12/24	Transcript : Novartis AG - Special Call
21/11/24	Transcript : Novartis AG - Shareholder/Analyst Call
29/10/24	Transcript : Novartis AG, Q3 2024 Earnings Call, Oct 29, 2024
28/10/24	Transcript : Novartis AG - Shareholder/Analyst Call
18/07/24	Transcript : Novartis AG, Q2 2024 Earnings Call, Jul 18, 2024
23/04/24	Transcript : Novartis AG, Q1 2024 Earnings Call, Apr 23, 2024
05/03/24	Transcript : Novartis AG - Shareholder/Analyst Call
06/02/24	Transcript : MorphoSys AG, Novartis AG - M&A Call
31/01/24	Transcript : Novartis AG, 2023 Earnings Call, Jan 31, 2024
08/01/24	Transcript : Novartis AG Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM
28/11/23	Transcript : Novartis AG - Special Call
13/11/23	Transcript : Novartis AG - Special Call